Tasigna in Glivec-resistant or Intolerant Patients in CML
Phase 4
Completed
- Conditions
- Imatinib IntolerantCMLNilotinibImatinib Resistant
- Interventions
- First Posted Date
- 2010-09-21
- Last Posted Date
- 2017-02-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 93
- Registration Number
- NCT01206088
- Locations
- 🇰🇷
St. Mary hospital, Catholic medical center, Seoul, Korea, Republic of
Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy
- First Posted Date
- 2010-09-16
- Last Posted Date
- 2015-03-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 616
- Registration Number
- NCT01202903
- Locations
- 🇨🇳
Novartis Investigative Site, Shanghai, China
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- First Posted Date
- 2010-09-15
- Last Posted Date
- 2013-09-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 2144
- Registration Number
- NCT01202188
- Locations
- 🇯🇵
Novartis Inverstigative Site, Iwata, Japan
🇭🇺Novartis INvestigative Site, Balassagyarmat, Hungary
🇦🇺Novartis Investigative site, New lambton, Australia
Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis
- First Posted Date
- 2010-09-14
- Last Posted Date
- 2021-04-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 4125
- Registration Number
- NCT01201356
- Locations
- 🇬🇧
Novartis Investigative Site, Swindon, United Kingdom
Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy
Phase 3
Terminated
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- Biological: RituximabBiological: Ofatumumab
- First Posted Date
- 2010-09-13
- Last Posted Date
- 2018-05-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 438
- Registration Number
- NCT01200589
- Locations
- 🇺🇦
Novartis Investigative Site, Simferopil, Ukraine
Safety, Tolerability and Pharmacokinetics of QAK423A in Healthy Volunteers and Chronic Obstructive Pulmonary Disease (COPD) Patients
- First Posted Date
- 2010-09-09
- Last Posted Date
- 2010-09-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 76
- Registration Number
- NCT01197287
- Locations
- 🇩🇪
Novartis Investigative Site, Berlin, Germany
1 Year Open-label Extension to CZOL446H2337 Safety and Efficacy Trial of Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids
- First Posted Date
- 2010-09-09
- Last Posted Date
- 2019-09-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 25
- Registration Number
- NCT01197300
- Locations
- 🇬🇧
Novartis Investigative Site, West Midlands, Birmingham, United Kingdom
A Study of BEZ235 in Adult Japanese Patients With Advanced Solid Tumors
- First Posted Date
- 2010-09-06
- Last Posted Date
- 2020-12-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 35
- Registration Number
- NCT01195376
- Locations
- 🇯🇵
Novartis Investigative Site, Yufu, Oita, Japan
Efficacy and Safety of LCZ696 Compared to Placebo in Patients With Essential Hypertension
- First Posted Date
- 2010-09-01
- Last Posted Date
- 2016-02-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 389
- Registration Number
- NCT01193101
- Locations
- 🇹🇭
Novartis Investigative Site, Chiang Mai, Thailand
Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis
- First Posted Date
- 2010-08-20
- Last Posted Date
- 2018-03-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 185
- Registration Number
- NCT01185821
- Locations
- 🇹🇷
Novartis Investigative Site, Kocaeli, Turkey
© Copyright 2025. All Rights Reserved by MedPath